Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon Sep 25, 2020 11:57am
155 Views
Post# 31620315

RE:RE:RE:RE:RE:RE:RE:We are waiting for an explanation Realstocky

RE:RE:RE:RE:RE:RE:RE:We are waiting for an explanation RealstockyThere will come a time after a certain amount of execution (including a BLA approval) when this current management team (who definitely dont overpromise, lol) get credibility for doing what they say and other companies begin to see the other applications in acute injury area and severe burns for Ryplazim for one example. If the multiple ascending trials on 4050 allow 2400 mg dosage and there is a 2nd phase trial with efficacy already found with 800 and 1200mg, we may see some even better results. Since safety has never been a concern with 4050 and efficacy good even at low dosages, John Moran referred to it as penicillin as it showed efficacy on 6 organs in open label trials. Question is why did they wait so long to increase dosages? Alstrom was particularly incredible with that nasty multi-organ disease being turned around. If they can lower burn while doing focused trials ASAP, this may make some money for people other than just thomvest. Just not in the next 6 months but there should be some speculation beginning to build someday soon. 

stockman6767 wrote:
Sah1,I suspect that part of the difference in our estimation is that I am willing to throw in an overage for the high momentum this stock shows when on the move probably due to the low amount of share available om the open market as at least 85% of the shares are held by the  majority owners. We have witness this volatility due this momentum trading on the previous spikes on covid news.As an aside. I am totally baffled by the seeming lack of interest by LMNL management to look at 4050 as a possible treatment for those suffering the serious symptoms of Covid. As I understand it, most of the cause of serious harm relates to inflamatory damage brought on by the virus. Yet inflamation is the main issue hopefully treated by 4050. It would seem to me, this would at least be worth investigating. But the only thing we hear about is the low revenue avenue of blood collection and sale. A treatment based on 4050 would be worth a fortune and the mere mention of an investigation into this possibility would cause a huge immediate spike in share value as we have seen  in the recent no news spikes other then belonging to the Covid group (forgot their exact name)>
<< Previous
Bullboard Posts
Next >>